409 related articles for article (PubMed ID: 30579366)
21. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Cho SH; Lee WS; Joo YD
Ann Hematol; 2013 Jul; 92(7):889-97. PubMed ID: 23420388
[TBL] [Abstract][Full Text] [Related]
22. [Application of DNA methyltransferase inhibitors for myelodysplastic syndrome].
Lü XY; Du YX; Dai ZH; Liu M; Liu XY; Zhang KL
Yi Chuan; 2013 Feb; 35(2):136-40. PubMed ID: 23448925
[TBL] [Abstract][Full Text] [Related]
23. Quantification of unmethylated Alu (QUAlu): a tool to assess global hypomethylation in routine clinical samples.
Buj R; Mallona I; Díez-Villanueva A; Barrera V; Mauricio D; Puig-Domingo M; Reverter JL; Matias-Guiu X; Azuara D; Ramírez JL; Alonso S; Rosell R; Capellà G; Perucho M; Robledo M; Peinado MA; Jordà M
Oncotarget; 2016 Mar; 7(9):10536-46. PubMed ID: 26859682
[TBL] [Abstract][Full Text] [Related]
24. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
25. Differential repetitive DNA methylation in multiple myeloma molecular subgroups.
Bollati V; Fabris S; Pegoraro V; Ronchetti D; Mosca L; Deliliers GL; Motta V; Bertazzi PA; Baccarelli A; Neri A
Carcinogenesis; 2009 Aug; 30(8):1330-5. PubMed ID: 19531770
[TBL] [Abstract][Full Text] [Related]
26. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
Aparicio A; North B; Barske L; Wang X; Bollati V; Weisenberger D; Yoo C; Tannir N; Horne E; Groshen S; Jones P; Yang A; Issa JP
Epigenetics; 2009 Apr; 4(3):176-84. PubMed ID: 19421002
[TBL] [Abstract][Full Text] [Related]
27. Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.
Kalinkova L; Sevcikova A; Stevurkova V; Fridrichova I; Ciernikova S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614080
[TBL] [Abstract][Full Text] [Related]
28. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.
Abbas HA; Reville PK; Jiang X; Yang H; Reuben A; Im JS; Little L; Sinson JC; Chen K; Futreal A; Garcia-Manero G
Front Immunol; 2021; 12():659625. PubMed ID: 33912187
[TBL] [Abstract][Full Text] [Related]
29. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
Tohyama K
Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
[TBL] [Abstract][Full Text] [Related]
30. Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL.
Subhash S; Andersson PO; Kosalai ST; Kanduri C; Kanduri M
Clin Epigenetics; 2016; 8():106. PubMed ID: 27777635
[TBL] [Abstract][Full Text] [Related]
31. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
32. Immunological effects of hypomethylating agents.
Lindblad KE; Goswami M; Hourigan CS; Oetjen KA
Expert Rev Hematol; 2017 Aug; 10(8):745-752. PubMed ID: 28644756
[TBL] [Abstract][Full Text] [Related]
33. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
Abáigar M; Ramos F; Benito R; Díez-Campelo M; Sánchez-del-Real J; Hermosín L; Rodríguez JN; Aguilar C; Recio I; Alonso JM; de las Heras N; Megido M; Fuertes M; del Cañizo MC; Hernández-Rivas JM
Ann Hematol; 2013 Nov; 92(11):1543-52. PubMed ID: 23740492
[TBL] [Abstract][Full Text] [Related]
35. DNA Methylation Analysis Using Droplet Digital PCR.
Yu M; Heinzerling TJ; Grady WM
Methods Mol Biol; 2018; 1768():363-383. PubMed ID: 29717454
[TBL] [Abstract][Full Text] [Related]
36. Repetitive genomic elements and overall DNA methylation changes in acute myeloid and childhood B-cell lymphoblastic leukemia patients.
Bujko M; Musialik E; Olbromski R; Przestrzelska M; Libura M; Pastwińska A; Juszczyński P; Zwierzchowski L; Baranowski P; Siedlecki JA
Int J Hematol; 2014 Jul; 100(1):79-87. PubMed ID: 24841671
[TBL] [Abstract][Full Text] [Related]
37. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
38. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
Raval A; Lucas DM; Matkovic JJ; Bennett KL; Liyanarachchi S; Young DC; Rassenti L; Kipps TJ; Grever MR; Byrd JC; Plass C
J Clin Oncol; 2005 Jun; 23(17):3877-85. PubMed ID: 15809452
[TBL] [Abstract][Full Text] [Related]
39. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
Kuykendall JR
Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Lübbert M
Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]